BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 15848661)

  • 1. Living donor liver transplantation for hepatocellular carcinoma: a special reference to a preoperative des-gamma-carboxy prothrombin value.
    Shimada M; Yonemura Y; Ijichi H; Harada N; Shiotani S; Ninomiya M; Terashi T; Yoshizumi T; Soejima Y; Maehara Y
    Transplant Proc; 2005 Mar; 37(2):1177-9. PubMed ID: 15848661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation.
    Taketomi A; Sanefuji K; Soejima Y; Yoshizumi T; Uhciyama H; Ikegami T; Harada N; Yamashita Y; Sugimachi K; Kayashima H; Iguchi T; Maehara Y
    Transplantation; 2009 Feb; 87(4):531-7. PubMed ID: 19307789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended indication for living donor liver transplantation in patients with hepatocellular carcinoma.
    Soejima Y; Taketomi A; Yoshizumi T; Uchiyama H; Aishima S; Terashi T; Shimada M; Maehara Y
    Transplantation; 2007 Apr; 83(7):893-9. PubMed ID: 17460559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy.
    Yamamoto K; Imamura H; Matsuyama Y; Hasegawa K; Beck Y; Sugawara Y; Makuuchi M; Kokudo N
    Ann Surg Oncol; 2009 Oct; 16(10):2795-804. PubMed ID: 19669841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of histological vascular invasion from preoperative evaluation in patients with hepatocellular carcinoma who underwent living donor liver transplantation.
    Sakai K; Okajima H; Koshino K; Suzuki T; Nobori S; Matsuyama M; Ushigome H; Ochiai T; Yoshimura N
    Transplant Proc; 2012 Mar; 44(2):409-11. PubMed ID: 22410029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The predictors of microvascular invasion in candidates for liver transplantation with hepatocellular carcinoma-with special reference to the serum levels of des-gamma-carboxy prothrombin.
    Shirabe K; Itoh S; Yoshizumi T; Soejima Y; Taketomi A; Aishima S; Maehara Y
    J Surg Oncol; 2007 Mar; 95(3):235-40. PubMed ID: 17323337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma.
    Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Takasaki K; Takenami K; Yamamoto M; Nakano M
    Cancer; 2000 Feb; 88(3):544-9. PubMed ID: 10649245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of anatomical resection and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma.
    Imamura H; Matsuyama Y; Miyagawa Y; Ishida K; Shimada R; Miyagawa S; Makuuchi M; Kawasaki S
    Br J Surg; 1999 Aug; 86(8):1032-8. PubMed ID: 10460639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Des-gamma-carboxy prothrombin in cancer and non-cancer liver tissue of patients with hepatocellular carcinoma.
    Tang W; Miki K; Kokudo N; Sugawara Y; Imamura H; Minagawa M; Yuan LW; Ohnishi S; Makuuchi M
    Int J Oncol; 2003 May; 22(5):969-75. PubMed ID: 12684661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurement of serum levels of des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma by a revised enzyme immunoassay kit with increased sensitivity.
    Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Watanabe K; Magario N; Yokoo T; Naraki T
    Cancer; 1999 Feb; 85(4):812-8. PubMed ID: 10091758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Living-donor liver transplantation for hepatocellular carcinoma.
    Kaihara S; Kiuchi T; Ueda M; Oike F; Fujimoto Y; Ogawa K; Kozaki K; Tanaka K
    Transplantation; 2003 Feb; 75(3 Suppl):S37-40. PubMed ID: 12589138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison between human-telomerase reverse transcriptase mRNA and alpha-fetoprotein mRNA as a predictive value for recurrence of hepatocellular carcinoma in living donor liver transplantation.
    Oya H; Sato Y; Yamamoto S; Nakatsuka H; Kobayashi T; Hara Y; Waguri N; Suda T; Aoyagi Y; Hatakeyama K
    Transplant Proc; 2006 Dec; 38(10):3636-9. PubMed ID: 17175353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can we expand the Milan criteria for hepatocellular carcinoma in living donor liver transplantation?
    Lee KW; Park JW; Joh JW; Kim SJ; Choi SH; Heo JS; Lee HH; Lee DS; Park JH; Yoo BC; Paik SW; Koh KC; Lee JH; Choi MS; Lee SK
    Transplant Proc; 2004 Oct; 36(8):2289-90. PubMed ID: 15561222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation.
    Ito T; Takada Y; Ueda M; Haga H; Maetani Y; Oike F; Ogawa K; Sakamoto S; Ogura Y; Egawa H; Tanaka K; Uemoto S
    Liver Transpl; 2007 Dec; 13(12):1637-44. PubMed ID: 18044766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A revised scoring system utilizing serum alphafetoprotein levels to expand candidates for living donor transplantation in hepatocellular carcinoma.
    Yang SH; Suh KS; Lee HW; Cho EH; Cho JY; Cho YB; Kim IH; Yi NJ; Lee KU
    Surgery; 2007 May; 141(5):598-609. PubMed ID: 17462459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact of des-γ-carboxyl prothrombin in living-donor liver transplantation for recurrent hepatocellular carcinoma.
    Harimoto N; Yoshida Y; Kurihara T; Takeishi K; Itoh S; Harada N; Tsujita E; Yamashita YI; Uchiyama H; Soejima Y; Ikegami T; Yoshizumi T; Kawanaka H; Ikeda T; Shirabe K; Saeki H; Oki E; Kimura Y; Maehara Y
    Transplant Proc; 2015 Apr; 47(3):703-4. PubMed ID: 25819732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrent hepatocellular carcinoma after transplantation: use of a pathological score on explanted livers to predict recurrence.
    Parfitt JR; Marotta P; Alghamdi M; Wall W; Khakhar A; Suskin NG; Quan D; McAllister V; Ghent C; Levstik M; McLean C; Chakrabarti S; Garcia B; Driman DK
    Liver Transpl; 2007 Apr; 13(4):543-51. PubMed ID: 17394152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC.
    Toyoda H; Kumada T; Kaneoka Y; Osaki Y; Kimura T; Arimoto A; Oka H; Yamazaki O; Manabe T; Urano F; Chung H; Kudo M; Matsunaga T
    J Hepatol; 2008 Aug; 49(2):223-32. PubMed ID: 18571271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma.
    Aoyagi Y; Oguro M; Yanagi M; Mita Y; Suda T; Suzuki Y; Hata K; Ichii K; Asakura H
    Cancer; 1996 May; 77(9):1781-6. PubMed ID: 8646674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation methods for pretransplant oncologic markers and their prognostic impacts in patient undergoing living donor liver transplantation for hepatocellular carcinoma.
    Shindoh J; Sugawara Y; Nagata R; Kaneko J; Tamura S; Aoki T; Sakamoto Y; Hasegawa K; Tanaka T; Kokudo N
    Transpl Int; 2014 Apr; 27(4):391-8. PubMed ID: 24472068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.